Table 4.

The expression profile of miRNAs regulating the expression of selected mRNAs in HaCaT treated with LPS and next Adalimumab or cyclosporine A after 2, 8, and 24 hours of exposure in comparison to the control culture.

Group	miRNA	H_2 vs C	H_8 vs C	H_24 vs C
HaCaT + LPS	hsa-miR-3202	+2.41 ± 0.22*	+2.87 ± 0.18*	+2.09 ± 0.47*
	hsa-miR-3915	+3.45 ± 0.15*	+3.14 ± 0.24*	−1.08 ± 0.09*
	hsa-miR-27a-5p	−2.98 ± 0.36*	−3.14 ± 0.17*	−4.08 ± 0.27*
	hsa-miR-382	+2.01 ± 0.19*	+1.59 ± 0.12*	−1.41 ± 0.12*
HaCaT + LPS+ adalimumab	hsa-miR-33a-5p	−2.01 ± 0.22*	−2.11 ± 0.19*	−2.18 ± 0.22*
	hsa-miR-382	+4.74 ± 0.26*	+3.69 ± 0.24*	+2.01 ± 0.42*
	hsa-miR-3202	−3.69 ± 0.36*	−3.47 ± 0.41*	−5.01 ± 0.33*
	hsa-miR-583	−2.41 ± 0.17*	−4.84 ± 0.33*	−4.11 ± 0.17*
	hsa-miR-1-3p	+2.01 ± 0.21*	+1.41 ± 0.17*	−1.01 ± 0.08*
	hsa-miR-1275	−8.14 ± 0.41*	−4.45 ± 0.99*	−2.85 ± 0.22*
	hsa-miR-27a-5p	+3.33 ± 0.34*	+3.41 ± 0.28*	+3.89 ± 0.37*
HaCaT + LPS + cyclosporine A	hsa-miR-4696	−2.14 ± 0.15*	−4.08 ± 0.42*	−2.89 ± 0.46*
	hsa-miR-1275	+5.14 ± 0.29*	+7.14 ± 0.77*	+6.58 ± 0.52*
	hsa-miR-583	−2.01 ± 0.36*	+1.14 ± 0.44*	+1.89 ± 0.36*
	hsa-miR-575	+3.06 ± 0.34*	+3.47 ± 0.62*	+2.54 ± .74*

C- control HaCaT cell culture; LPS lipopolysaccharide A; H_2, H_8, H_24 – HaCaT treated with LPS for 8 hours and next adalimumab or cyclosporine A for 2, 8 and,24 hours; (+) – overexpression in comparison to the control; (-) – downregulated in comparison to the control; * – p < vs. C; 0.05; mean ± standard deviation.